<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01303029</url>
  </required_header>
  <id_info>
    <org_study_id>TTD-10-01</org_study_id>
    <secondary_id>2010-022599-30</secondary_id>
    <nct_id>NCT01303029</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer</brief_title>
  <acronym>GECA</acronym>
  <official_title>A Phase IIb Randomized Study to Evaluate the Efficacy of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy of the combination of
      gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in patients with metastatic
      pancreatic cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (RR)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of rash in patients treated with erlotinib and progression free survival and overall survival and treatment relationship</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine+erlotinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine+erlotinib+capecitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine+erlotinib</intervention_name>
    <description>Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine+erlotinib+capecitabine</intervention_name>
    <description>Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Capecitabine will be administered orally 1.660 mg/m2 day from day 1 to day 21. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to understand and willingness to sign a written informed consent

          2. Able, in the investigator's opinion, to fulfill the procedures and explorations of the
             study

          3. Age ≥ 18 years old

          4. ECOG 0-2

          5. Life expectancy ≥ 12 weeks

          6. Patients with metastatic adenocarcinoma of the pancreas, following 7th edition of TNM
             classification

          7. Histologically or cytologically confirmed diagnosis of adenocarcinoma of the pancreas

          8. Measurable disease following RECIST criteria version 1.1

          9. No previous systemic treatment for metastatic pancreatic cancer Adjuvant chemotherapy
             al least 6 months before enrollment is allowed. Patients having neoadjuvant
             chemotherapy must have completed the treatment at least 4 weeks before trial entry.
             Toxicities associated to previous treatment must be resolved before enrollment.
             Progression disease (metastatic disease) must be confirmed after adjuvant treatment

         10. Adequate bone marrow function as determined by:

               -  Hemoglobin: ≥ 9 g/dL. (patients with hemoglobin &lt; 9 g/dL could be transfused
                  before their inclusion on the study)

               -  Platelets: ≥ 100 x 109/L

               -  Absolute Neutrophil account (ANC) ≥ 1,5 x 109/L

         11. Adequate liver function, as determined by:

               -  Serum bilirubin ≤ 1,5 x LSN

               -  AST, ALT ≤ 2,5 x LSN in patients without liver metastasis. In patients with liver
                  metastasis ≤ 5 x LSN

               -  Alkaline phosphatase ≤ 2,5 x LSN or ≤ 5 x LSN in patients with liver metastasis.
                  In patients with bone metastasis ≤ 10 x LSN

         12. Adequate renal function, as determined by:

               -  Creatinine clearance using the Cockcroft-Gault formula ≥ 50.0 ml/min

         13. Women of childbearing potential must have a negative serum or urine pregnancy test
             performed within 7 days prior to randomization. Postmenopausal women are defined as
             those who have been amenorrheic for at least 12 months. Also, both men and women
             enrolled in this study must use adequate birth control (eg., abstinence, intrauterine
             device, oral contraceptive or double barrier method or be surgically sterile),
             starting at the signing of the informed consent and up to at least 6 months after
             completion of treatment or the last dose, whichever occurs first

         14. Patients must not have undergone a major surgical procedure within 4 weeks prior to
             study treatment. The surgical wound should be completely healed

        Exclusion Criteria:

          1. Local pancreatic cancer (stage IA-IIB) or locally advance cancer (stage III),
             following the TNM 7th edition classification. Patients with metastatic disease that
             relapse after the initial diagnosis of local or advance disease could be included in
             this study

          2. Pancreatic endocrine tumor and ampulloma

          3. Evidence of carcinomatosis meningitis or brain metastasis. In case of clinical
             suspicious of brain metastasis is mandatory to perform a brain TAC/MR 4 weeks prior de
             inclusion.

          4. Primary tumors developed 5 years previous to the inclusion, except in situ cervix
             carcinoma or skin basocellular cancer properly treated

          5. Cardiovascular disease clinically significant (active):

               -  Non-controlled arterial hypertension (Systolic pressure &gt; 150 mg Hg and/or
                  diastolic pressure &gt; 100 mm Hg on repeated pressure measurements)

               -  Cerebrovascular accident/ictus (≤ 6 weeks prior to inclusion)

               -  Myocardial infarction (≤ 6 months prior to inclusion)

               -  Unstable angina

               -  Congestive cardiac insufficiency (grade II or superior following to New York
                  Heart Association (NYHA)

               -  Severe cardiac arrythmia requiring treatment

          6. Significant ophthalmologic anomalies

          7. Deficit in Dihydropyrimidine-Dehydrogenase (DPD)

          8. Unable to take oral drug. Previous surgical process that affect the absorption or make
             the needed to have intravenous feeding or parenteral nutrition with lipids

          9. Pregnancy women or in lactation period

         10. Antineoplastic treatment (chemotherapy, hormonal treatment, radiotherapy, surgery,
             biological therapy or tumor embolization) 4 weeks prior the inclusion

         11. Previous treatment with capecitabine or EGFR inhibitor

         12. Metabolic disease or any other disease which, in the investigator's opinion, might
             interfere with the treatment in study

         13. Known hypersensibility to any study drug (gemcitabine, erlotinib, capecitabine) or to
             5-fluorouracile and fluoropyrimidines

         14. Current infection grade ≥ 2 (CTCAE)

         15. Known human immunodeficiency virus infection, or chronic infection with hepatitis B or
             C virus, or severe uncontrolled intercurrent infection or other severe uncontrolled
             concomitant diseases

         16. Medical, psychological, psychiatric or sociological conditions that would interfere to
             the patient participation in the study or in the assessment of the results

         17. Current or 30 days previous to study treatment with other investigational drug or
             participation in other trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Irigoyen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital de Toledo, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Benavides, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Carlos Haya, Málaga. Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish Cooperative Group for Digestive Tumour Therapy</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.ttdgroup.org</url>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2011</study_first_submitted>
  <study_first_submitted_qc>February 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>erlotinib</keyword>
  <keyword>capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

